| # | Pathway | Proteins |
|---|
| 1 | Malaria | ENSAPLP00000016307, ENSAPLP00000007488, ENSAPLP00000005443, ENSAPLP00000011743 |
| 2 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000016339, ENSAPLP00000014420 |
| 3 | African trypanosomiasis | ENSAPLP00000016307, ENSAPLP00000011291, ENSAPLP00000007488, ENSAPLP00000005443 |
| 4 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000016339 |
| 5 | Ribosome | ENSAPLP00000008397, ENSAPLP00000007673, ENSAPLP00000008818, ENSAPLP00000009200, ENSAPLP00000015238, ENSAPLP00000015617, ENSAPLP00000014372 |
| 6 | Lysine degradation | ENSAPLP00000010985, ENSAPLP00000008955, ENSAPLP00000014420 |
| 7 | Neuroactive ligand-receptor interaction | ENSAPLP00000004168, ENSAPLP00000013537 |
| 8 | Complement and coagulation cascades | ENSAPLP00000010484, ENSAPLP00000013537, ENSAPLP00000006069, ENSAPLP00000003063 |
| 9 | Proteoglycans in cancer | ENSAPLP00000005854, ENSAPLP00000008057, ENSAPLP00000011483, ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000004826, ENSAPLP00000013792 |
| 10 | Pathogenic Escherichia coli infection | ENSAPLP00000012724, ENSAPLP00000009107, ENSAPLP00000005826, ENSAPLP00000015503 |
| 11 | Butirosin and neomycin biosynthesis | ENSAPLP00000009741 |
| 12 | Dilated cardiomyopathy | ENSAPLP00000012522, ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000012136 |
| 13 | Mineral absorption | ENSAPLP00000009906, ENSAPLP00000015679 |
| 14 | Leishmaniasis | ENSAPLP00000009107, ENSAPLP00000011291 |
| 15 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000011483, ENSAPLP00000011291, ENSAPLP00000004168 |
| 16 | Asthma | ENSAPLP00000011291 |
| 17 | Systemic lupus erythematosus | ENSAPLP00000011291, ENSAPLP00000004168, ENSAPLP00000001720 |
| 18 | Platelet activation | ENSAPLP00000008057, ENSAPLP00000011483, ENSAPLP00000009107, ENSAPLP00000009088 |
| 19 | Primary bile acid biosynthesis | ENSAPLP00000009740 |
| 20 | Nitrogen metabolism | ENSAPLP00000002717 |
| 21 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000012522, ENSAPLP00000009107, ENSAPLP00000012136 |
| 22 | Transcriptional misregulation in cancer | ENSAPLP00000011291, ENSAPLP00000013972 |
| 23 | Allograft rejection | ENSAPLP00000011291 |
| 24 | Synthesis and degradation of ketone bodies | ENSAPLP00000014420 |
| 25 | Glutathione metabolism | ENSAPLP00000005537, ENSAPLP00000007097 |
| 26 | Prostate cancer | ENSAPLP00000005537, ENSAPLP00000014548 |
| 27 | ECM-receptor interaction | ENSAPLP00000011483, ENSAPLP00000009107, ENSAPLP00000004826 |
| 28 | Carbohydrate digestion and absorption | ENSAPLP00000009741 |
| 29 | Intestinal immune network for IgA production | ENSAPLP00000011291 |
| 30 | Phenylalanine metabolism | ENSAPLP00000005038 |
| 31 | Proximal tubule bicarbonate reclamation | ENSAPLP00000002717 |
| 32 | PPAR signaling pathway | ENSAPLP00000005715, ENSAPLP00000009282 |
| 33 | Protein digestion and absorption | ENSAPLP00000011483, ENSAPLP00000012993 |
| 34 | Primary immunodeficiency | ENSAPLP00000011291 |
| 35 | Dorso-ventral axis formation | ENSAPLP00000016323 |
| 36 | Collecting duct acid secretion | ENSAPLP00000002717 |
| 37 | Autoimmune thyroid disease | ENSAPLP00000011291 |
| 38 | Terpenoid backbone biosynthesis | ENSAPLP00000014420 |
| 39 | Type II diabetes mellitus | ENSAPLP00000009741 |
| 40 | Renin-angiotensin system | ENSAPLP00000004168 |
| 41 | RNA degradation | ENSAPLP00000001295, ENSAPLP00000003473 |
| 42 | Bile secretion | ENSAPLP00000002717 |
| 43 | Regulation of lipolysis in adipocytes | ENSAPLP00000005715 |
| 44 | Bladder cancer | ENSAPLP00000013972 |
| 45 | Notch signaling pathway | ENSAPLP00000016323 |
| 46 | Epstein-Barr virus infection | ENSAPLP00000015706, ENSAPLP00000011291, ENSAPLP00000011722, ENSAPLP00000011777 |
| 47 | Proteasome | ENSAPLP00000015706, ENSAPLP00000011722 |
| 48 | NOD-like receptor signaling pathway | ENSAPLP00000014548 |
| 49 | Estrogen signaling pathway | ENSAPLP00000013972, ENSAPLP00000014548 |
| 50 | Metabolism of xenobiotics by cytochrome P450 | ENSAPLP00000005537 |
| 51 | Endometrial cancer | ENSAPLP00000009282 |
| 52 | Drug metabolism - cytochrome P450 | ENSAPLP00000005537 |
| 53 | Focal adhesion | ENSAPLP00000008057, ENSAPLP00000011483, ENSAPLP00000009107, ENSAPLP00000009088, ENSAPLP00000009282 |
| 54 | Hematopoietic cell lineage | ENSAPLP00000011291 |
| 55 | Butanoate metabolism | ENSAPLP00000014420 |
| 56 | Hepatitis B | ENSAPLP00000013972, ENSAPLP00000004826 |
| 57 | Vascular smooth muscle contraction | ENSAPLP00000008057, ENSAPLP00000002381 |
| 58 | Galactose metabolism | ENSAPLP00000009741 |
| 59 | Tyrosine metabolism | ENSAPLP00000005038 |
| 60 | Amphetamine addiction | ENSAPLP00000008057 |
| 61 | Fructose and mannose metabolism | ENSAPLP00000009741 |
| 62 | HIF-1 signaling pathway | ENSAPLP00000015679, ENSAPLP00000009741 |
| 63 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000012522, ENSAPLP00000009107 |
| 64 | Chemical carcinogenesis | ENSAPLP00000005537 |
| 65 | Phagosome | ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000015503 |
| 66 | Tryptophan metabolism | ENSAPLP00000014420 |
| 67 | NF-kappa B signaling pathway | ENSAPLP00000011291 |
| 68 | Staphylococcus aureus infection | ENSAPLP00000011291 |
| 69 | Alcoholism | ENSAPLP00000008057, ENSAPLP00000001720 |
| 70 | Starch and sucrose metabolism | ENSAPLP00000009741 |
| 71 | Legionellosis | ENSAPLP00000009114 |
| 72 | Rheumatoid arthritis | ENSAPLP00000011291 |
| 73 | Apoptosis | ENSAPLP00000009010 |
| 74 | Viral carcinogenesis | ENSAPLP00000015706, ENSAPLP00000001720, ENSAPLP00000011777 |
| 75 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000008057, ENSAPLP00000012136 |
| 76 | PI3K-Akt signaling pathway | ENSAPLP00000011483, ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000014548 |
| 77 | Protein processing in endoplasmic reticulum | ENSAPLP00000014094, ENSAPLP00000010630, ENSAPLP00000014548 |
| 78 | Pertussis | ENSAPLP00000009107 |
| 79 | B cell receptor signaling pathway | ENSAPLP00000011291 |
| 80 | Long-term potentiation | ENSAPLP00000008057 |
| 81 | Pancreatic secretion | ENSAPLP00000002717 |
| 82 | Insulin signaling pathway | ENSAPLP00000008057, ENSAPLP00000009741 |
| 83 | Amino sugar and nucleotide sugar metabolism | ENSAPLP00000009741 |
| 84 | Inflammatory mediator regulation of TRP channels | ENSAPLP00000008057 |
| 85 | Central carbon metabolism in cancer | ENSAPLP00000009741 |
| 86 | Thyroid hormone synthesis | ENSAPLP00000014548 |
| 87 | Propanoate metabolism | ENSAPLP00000014420 |
| 88 | TNF signaling pathway | ENSAPLP00000013972 |
| 89 | Natural killer cell mediated cytotoxicity | ENSAPLP00000011291 |
| 90 | Ribosome biogenesis in eukaryotes | ENSAPLP00000006775 |
| 91 | Fc epsilon RI signaling pathway | ENSAPLP00000011291 |
| 92 | Glyoxylate and dicarboxylate metabolism | ENSAPLP00000014420 |
| 93 | Salivary secretion | ENSAPLP00000009817 |
| 94 | Arginine and proline metabolism | ENSAPLP00000007097 |
| 95 | Bacterial invasion of epithelial cells | ENSAPLP00000009107, ENSAPLP00000009282 |
| 96 | MicroRNAs in cancer | ENSAPLP00000016323, ENSAPLP00000013972 |
| 97 | Leukocyte transendothelial migration | ENSAPLP00000009107, ENSAPLP00000013972 |
| 98 | Cardiac muscle contraction | ENSAPLP00000012136 |
| 99 | Viral myocarditis | ENSAPLP00000011291 |
| 100 | Measles | ENSAPLP00000011291 |
| 101 | RNA transport | ENSAPLP00000009114, ENSAPLP00000006298, ENSAPLP00000005892 |
| 102 | Gastric acid secretion | ENSAPLP00000002717 |
| 103 | Citrate cycle (TCA cycle) | ENSAPLP00000008955 |
| 104 | Insulin resistance | ENSAPLP00000008057 |
| 105 | Prion diseases (no map in kegg database) | ENSAPLP00000016323 |
| 106 | Fatty acid metabolism (no map in kegg database) | ENSAPLP00000014420 |
| 107 | Carbon metabolism (no map in kegg database) | ENSAPLP00000009741, ENSAPLP00000008955, ENSAPLP00000014420 |
| 108 | Pyruvate metabolism | ENSAPLP00000014420 |
| 109 | Fatty acid degradation | ENSAPLP00000014420 |
| 110 | Cell adhesion molecules (CAMs) | ENSAPLP00000009107 |
| 111 | Peroxisome | ENSAPLP00000009740 |
| 112 | Small cell lung cancer | ENSAPLP00000009107 |
| 113 | Rap1 signaling pathway | ENSAPLP00000009107, ENSAPLP00000009088 |
| 114 | Gap junction | ENSAPLP00000015503 |
| 115 | Lysosome | ENSAPLP00000004168, ENSAPLP00000006338 |
| 116 | Phospholipase D signaling pathway | ENSAPLP00000011291 |
| 117 | Shigellosis | ENSAPLP00000009107 |
| 118 | Thyroid hormone signaling pathway | ENSAPLP00000016323 |
| 119 | Pathways in cancer | ENSAPLP00000009107, ENSAPLP00000005537, ENSAPLP00000013972, ENSAPLP00000014548 |
| 120 | Regulation of actin cytoskeleton | ENSAPLP00000008057, ENSAPLP00000009107, ENSAPLP00000013537 |
| 121 | Oocyte meiosis | ENSAPLP00000008057 |
| 122 | Glycolysis / Gluconeogenesis | ENSAPLP00000009741 |
| 123 | mRNA surveillance pathway | ENSAPLP00000008057 |
| 124 | Valine, leucine and isoleucine degradation | ENSAPLP00000014420 |
| 125 | Fc gamma R-mediated phagocytosis | ENSAPLP00000011291 |
| 126 | Toxoplasmosis | ENSAPLP00000009107 |
| 127 | cAMP signaling pathway | ENSAPLP00000008057 |
| 128 | Hippo signaling pathway | ENSAPLP00000008057 |
| 129 | Axon guidance | ENSAPLP00000009107 |
| 130 | Dopaminergic synapse | ENSAPLP00000008057 |
| 131 | Calcium signaling pathway | ENSAPLP00000011291 |
| 132 | cGMP-PKG signaling pathway | ENSAPLP00000008057 |
| 133 | Tuberculosis | ENSAPLP00000011291 |
| 134 | Spliceosome | ENSAPLP00000004567, ENSAPLP00000012068 |
| 135 | Oxytocin signaling pathway | ENSAPLP00000008057 |
| 136 | Herpes simplex infection | ENSAPLP00000008057 |
| 137 | Endocytosis | ENSAPLP00000005705, ENSAPLP00000003542, ENSAPLP00000016193 |
| 138 | HTLV-I infection | ENSAPLP00000009088 |
| 139 | Parkinson's disease | ENSAPLP00000006744 |
| 140 | Alzheimer's disease | ENSAPLP00000011743 |
| 141 | Metabolic pathways (no map in kegg database) | ENSAPLP00000009740, ENSAPLP00000009741, ENSAPLP00000008955, ENSAPLP00000007097, ENSAPLP00000014420 |